Table 2.
Characteristics of HSCT recipients.
| Clinical variable | IA (N = 50) | Non-IA (N = 302) | RR | P |
|---|---|---|---|---|
| Age at transplantation–Mean ± S.D. | 37.3 (13.1) | 40.3 (15.0) | 0.988 | 0.130 |
| Females–n (%) | 26 (52.0) | 151 (50.0) | 1.080 | 0.780 |
| HLA matching, no. (%) | ||||
| Transplant from haploidentical- related donor | 35 (70.0%) | 146 (48.3%) | 2.440 | 0.003 |
| Transplant from half-matched related donor | 4 (8.0%) | 79 (26.2%) | 0.261 | 0.009 |
| Transplant from haploidentical unrelated donor | 6 (12.0%) | 51 (16.9%) | 0.669 | 0.350 |
| Transplant from half-matched unrelated donor | 5 (10.0%) | 26 (8.6%) | 1.100 | 0.830 |
| Underlying disease, no. (%) | ||||
| Acute leukemia (AML, ALL) | 32 (64.0%) | 231 (76.5%) | 0.592 | 0.078 |
| Lymphoma/myeloma (MM, HL, NHL-B) | 13 (26.0%) | 56 (18.5%) | 1.440 | 0.248 |
| Chronic leukemia (CML, CLL) | 3 (6.0%) | 14 (4.6%) | 1.310 | 0.660 |
| Other (SM, MDS, AA) | 2 (4.0%) | 1 (0.3%) | 6.020 | 0.003 |
| Advanced disease stage, no. (%) | 29 (58.0%) | 169 (56.0%) | 1.100 | 0.720 |
| Myeloablative conditioning regimen, no. (%) | ||||
| Total-body irradiation | 42 (84.0%) | 229 (75.8%) | 1.620 | 0.213 |
| No total-body irradiation | 8 (16.0%) | 73 (24.1%) | 0.617 | |
| CMV serology of donor and recipient, no. (%) | ||||
| CMV−/CMV− | 5 (10.0%) | 25 (8.3%) | 1.056 | 0.900 |
| CMV–/CMV+, CMV+/CMV– or CMV+/CMV+ | 45 (90.0%) | 277 (91.7%) | 0.947 | |
| GVHD, grade II to IV, no. (%) | 6 (12.0%) | 21 (7.0%) | 1.700 | 0.220 |
P-values were calculated using competing risk logistic regression models. Statistically significant results are marked in bold. IA, invasive aspergillosis; HLA, human leukocyte antigen; TBI, total body irradiation; CMV, cytomegalovirus; GVHD, graft-vs-host-disease.